← All trials
NCT04532333
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2020
- Primary completion
- May 31, 2021
- Completion date
- Jun 30, 2021
- First posted
- Aug 31, 2020
- Last posted
- Aug 31, 2020
- Enrollment
- 236
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Changhai HospitalLead sponsor
- Zhengzhou UniversityCollaborator
- Shandong UniversityCollaborator
- Changhai HospitalReponsible party - principal investigator
- Wuhan UniversityCollaborator
- Zhejiang UniversityCollaborator
- The First People's Hospital of ChangzhouCollaborator
- Changhai HospitalOverall official - principal investigator
- Zhengzhou UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.